Ignite Creation Date:
2024-05-06 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05717166
Status:
RECRUITING
Last Update Posted:
2023-10-12
First Post:
2023-01-26
Brief Title:
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor
Sponsor:
David Palma
Organization:
Lawson Health Research Institute
Study Overview
Official Title:
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SABR-SYNC
Brief Summary:
This study is a phase III multi-institutional randomized trial Patients will be randomized in a 12 ratio between current standard of care treatment Arm 1 vs standard of care treatment SABR Arm 2 to sites of known disease
Patients will be stratified by two of the strongest prognostic factors based on a large multi-institutional analysis3 histology Group 1 hormone-sensitive prostate cancer breast or renal Group 2 all others and number of metastases Group 1 1-3 Group 2 4-10
Patients will be stratified by two of the strongest prognostic factors based on a large multi-institutional analysis3 histology Group 1 hormone-sensitive prostate cancer breast or renal Group 2 all others and number of metastases Group 1 1-3 Group 2 4-10
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None